Hauptseite > Online First > Advanced Imaging in the Diagnosis and Response Assessment of High-Grade Glioma: AJR Expert Panel Narrative Review > print

001     1027030
005     20251010111343.0
024 7 _ |a 10.2214/AJR.23.30612
|2 doi
024 7 _ |a 0002-9580
|2 ISSN
024 7 _ |a 0361-803X
|2 ISSN
024 7 _ |a 0092-5381
|2 ISSN
024 7 _ |a 0092-5632
|2 ISSN
024 7 _ |a 1546-3141
|2 ISSN
024 7 _ |a 2769-8785
|2 ISSN
037 _ _ |a FZJ-2024-03596
082 _ _ |a 610
100 1 _ |a Hu, Leland S.
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Advanced Imaging in the Diagnosis and Response Assessment of High-Grade Glioma: AJR Expert Panel Narrative Review
260 _ _ |a Leesburg, Va.
|c 2025
|b American Roentgen Ray Society
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1760087190_3589
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Supported by NIH grants to L. S. Hu (nos.U01CA220378, U01CA250481,R01CA264992, R01CA221938, and R21NS082609).
520 _ _ |a This AJR Expert Panel Narrative Review explores the current status of advanced MRI and PET techniques for the posttherapeutic response assessment of high-grade adult-type gliomas, focusing on ongoing clinical controversies in current practice. Discussed techniques that complement conventional MRI and aid the differentiation of recurrent tumor from posttreatment effects include DWI and diffusion-tensor imaging; perfusion MRI techniques including dynamic susceptibility contrast (DSC), dynamic contrast-enhanced, and arterial spin labeling MRI; MR spectroscopy (MRS) including assessment of 2-hydroxyglutarate (2HG) concentration; glucose- and amino acid (AA)-based PET; and amide proton transfer imaging. Updated criteria for the Response Assessment in Neuro-Oncology are presented. Given the abundant supporting clinical evidence, the panel supports a recommendation that routine response assessment after high-grade glioma treatment should include perfusion MRI, particularly given the development of a consensus recommended DSC-MRI protocol. Although published studies support 2HG MRS and AA PET, these techniques' widespread adoption will likely require increased availability (for 2HG MRS) or increased insurance funding in the United States (for AA PET). The review concludes with a series of consensus opinions from the author panel, centered on the clinical integration of the advanced imaging techniques into posttreatment surveillance protocols.Keywords: PET; advanced MRI; high-grade glioma; posttreatment; surveillance.
536 _ _ |a 5252 - Brain Dysfunction and Plasticity (POF4-525)
|0 G:(DE-HGF)POF4-5252
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Smits, Marion
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Kaufmann, Timothy J.
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Knutsson, Linda
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Rapalino, Otto
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Galldiks, Norbert
|0 P:(DE-Juel1)143792
|b 5
700 1 _ |a Sundgrene, Pia C.
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Cha, Soonmee
|0 P:(DE-HGF)0
|b 7
773 _ _ |a 10.2214/AJR.23.30612
|g p. AJR.23.30612
|0 PERI:(DE-600)2012224-X
|n 1
|p AJR.23.30612
|t American journal of roentgenology
|v 224
|y 2025
|x 0002-9580
856 4 _ |u https://juser.fz-juelich.de/record/1027030/files/PDF.pdf
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/1027030/files/post-print.pdf
|y Restricted
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)143792
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5252
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-02-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-02-05
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b AM J ROENTGENOL : 2022
|d 2024-02-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-02-05
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-02-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-02-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-02-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-02-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-02-05
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b AM J ROENTGENOL : 2022
|d 2024-02-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-20
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-20
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b AM J ROENTGENOL : 2022
|d 2024-12-20
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b AM J ROENTGENOL : 2022
|d 2024-12-20
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21